Bio-Techne Corp (TECH)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$48.51

Buy

$49.21

arrow-down$-0.76 (-1.56%)

Prices updated at 28 May 2025, 23:26 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products.
NASDAQ
arrow-down-0.51%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Robert V. Baumgartner, C.P.A.
CEO
Mr. Kim Kelderman
Most recent earnings
30 Jun 2024
Fiscal year end
30 Jun 2024
Employees
3,100
Head office
614 McKinley Place N.E.
Minneapolis
United States
55413
mobile
+1 612 379-8854
letter
-
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Dr. Roeland Nusse,PhD
Independent Director
0.09m
Dr. Amy Herr, PhD
Independent Director
-
Mr. John L. Higgins
Independent Director
0.10m
Dr. Joseph D. Keegan, PhD
Independent Director
0.08m
Mr. Robert V. Baumgartner, C.P.A.
Chairman of the Board
0.21m
Ms. Julie L. Bushman
Independent Director
0.09m
Mr. James T. Hippel
Principal Accounting Officer, Executive Vice President and Chief Financial Officer
0.70m
Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A.
Independent Director
0.08m
Dr. Alpna Seth, PhD
Independent Director
0.08m
Mr. Kim Kelderman
President, Chief Executive Officer and Director
0.76m
Dr. Judith Klimovsky, M.D.
Independent Director
0.01m
Mr. William Geist
President, Protein Sciences
0.55m
Dr. Matthew McManus
President, Diagnostics and Genomics Segment
0.25m
Mr. Shane Bohnen
Senior Vice President, General Counsel and Corporate Secretary
0.34m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Vanguard Group Inc18,526,824
BlackRock Inc13,746,351
BlackRock, Inc.13,843,281
T. Rowe Price Associates, Inc.11,375,279
T Rowe Price Associates, Inc9,424,313

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
01 Nov 2024-
01 Nov 2024-
01 Nov 2024-
01 Nov 2024-
01 Nov 2024-
01 Nov 2024-
01 Nov 2024-
01 Nov 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
24 Oct 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.